Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE] (SAMOF-TPE)
Primary Purpose
Sepsis
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Therapeutic plasma exchange
Sponsored by
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
- Adult patients are eligible for inclusion if they have sepsis with refractory shock and evidence of organ failure.
Exclusion Criteria:
- Persons who are pregnant
- Persons who are incarcerated
- Acute surgical catastrophe without potential for intervention or source control
- Cardiac arrest with unknown neurologic status, including patients being treated with therapeutic hypothermia
- Presence of severe acute brain injury or severe dementia
- Cardiogenic, neurogenic, obstructive, or post-cardiotomy shock
- Acute pancreatitis with no established source of infection
Diabetic ketoacidosis as primary pathology
- Note: Septic patients who develop DKA are eligible for inclusion. However, patients in whom organ dysfunction and hemodynamic instability are due primarily to volume depletion and acidosis from DKA should not be included.
- Need for mechanical circulatory support
Prolonged acute illness with > 24 hours of pressor needs at enrollment and/or end organ damage with further care deemed to be "futile."
- NOTE: The time resets if a new inciting event leads to SAMOF.
- For example, if a patient has sepsis stabilized but requires operative intervention for source control within the initial 24 hours of admission and returns to the ICU with SAMOF, the patient is again eligible for randomization for the next 24 hours.
- Bedbound state or poor baseline functional status with ECOG performance status score ≥ 3
- Underlying terminal illness/malignancy with < 6 months life expectancy
- Advanced chronic liver disease/cirrhosis with evidence of portal hypertension
- Asplenia
- HIV with HARRT non-compliance
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Therapeutic plasma exchange
Standard care alone for sepsis
Arm Description
Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
Standard care for patients with sepsis induced multi-organ failure
Outcomes
Primary Outcome Measures
28-Day Mortality
28 days
Secondary Outcome Measures
Full Information
NCT ID
NCT03844542
First Posted
February 15, 2019
Last Updated
February 15, 2019
Sponsor
Forsyth Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03844542
Brief Title
Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]
Acronym
SAMOF-TPE
Official Title
Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 2019 (Anticipated)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
June 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Forsyth Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
5. Study Description
Brief Summary
The investigators prospective, randomized adult clinical trial investigates the therapeutic efficacy of early therapeutic plasma exchange as adjunct treatment to standard therapy in patients with refractory septic shock and multiple organ failure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Therapeutic plasma exchange
Arm Type
Experimental
Arm Description
Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
Arm Title
Standard care alone for sepsis
Arm Type
No Intervention
Arm Description
Standard care for patients with sepsis induced multi-organ failure
Intervention Type
Device
Intervention Name(s)
Therapeutic plasma exchange
Intervention Description
Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
Primary Outcome Measure Information:
Title
28-Day Mortality
Description
28 days
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients are eligible for inclusion if they have sepsis with refractory shock and evidence of organ failure.
Exclusion Criteria:
Persons who are pregnant
Persons who are incarcerated
Acute surgical catastrophe without potential for intervention or source control
Cardiac arrest with unknown neurologic status, including patients being treated with therapeutic hypothermia
Presence of severe acute brain injury or severe dementia
Cardiogenic, neurogenic, obstructive, or post-cardiotomy shock
Acute pancreatitis with no established source of infection
Diabetic ketoacidosis as primary pathology
Note: Septic patients who develop DKA are eligible for inclusion. However, patients in whom organ dysfunction and hemodynamic instability are due primarily to volume depletion and acidosis from DKA should not be included.
Need for mechanical circulatory support
Prolonged acute illness with > 24 hours of pressor needs at enrollment and/or end organ damage with further care deemed to be "futile."
NOTE: The time resets if a new inciting event leads to SAMOF.
For example, if a patient has sepsis stabilized but requires operative intervention for source control within the initial 24 hours of admission and returns to the ICU with SAMOF, the patient is again eligible for randomization for the next 24 hours.
Bedbound state or poor baseline functional status with ECOG performance status score ≥ 3
Underlying terminal illness/malignancy with < 6 months life expectancy
Advanced chronic liver disease/cirrhosis with evidence of portal hypertension
Asplenia
HIV with HARRT non-compliance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Philip Keith, MD
Phone
843.693.0412
Email
pkeith@salemchest.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jeremy Hodges, RPh
Phone
336.718.8729
Email
jlhodges@novanthealth.org
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]
We'll reach out to this number within 24 hrs